Recent Updates
Recently added Catalysts

IAM1363

Phase 1/2

HER2 Mutation-Related Tumors | Small Molecules | Oncology |Iambic Therapeutics, Inc.|Trials Updated: Nov 17, 2026

IAM1363 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Feb 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment463

FDA Designations

No designations recorded

IAM1363 clinical trials

IAM1363 · 1 trial · 13 indications

Phase 1/2 1
NCT06253871A Phase 1/2 Study of IAM1363 in HER2 CancersHER2 Mutation-Related Tumors
RECRUITING463 Analytics
PHASE1/PHASE2RECRUITING
A Phase 1/2 Study of IAM1363 in HER2 Cancers
HER2 Mutation-Related TumorsUnlock trial analytics

Study Endpoints

Primary Endpoints

Incidence and severity of dose limiting toxicities (DLTs) (Part 1 only)
21 days

Incidence and severity of DLTs during the first cycle of treatment in participants in Part 1

Incidence and severity of adverse events (AEs)
Through 30 days after the last dose of study drug (up to 90 days for Cohort 4D)

Incidence of treatment emergent AEs (TEAEs) and serious adverse events (SAEs)

Pharmacokinetic (PK) parameters
Up to 42 days

PK parameters. Includes but is not limited to assessment of maximum concentration (Cmax).

Confirmed objective response rate (cORR)
Through study completion, estimated as 57 months

Percentage of participants who achieve a confirmed objective response (complete response \[CR\] + partial response \[PR\]) per the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

Confirmed central nervous system ORR (CNS-cORR)
Through study completion, estimated as 57 months

Percentage of participants who achieve a confirmed CNS-cORR (CNS-CR + CNS-PR) per the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) Criteria

Frequency of IAM1363 dose modifications, including treatment discontinuations
Through 30 days after the last dose of study drug
Incidence and severity of clinical laboratory abnormalities
Through 30 days post last dose of study drug
Incidence of ECG abnormalities
Through 30 days after the last dose of study drug

As measured using standard ECG parameters, including pulse rate, QT intervals, and QRS duration.

Secondary Endpoints

Best overall response (BoR) rate
Through study completion, estimated as 57 months
Duration of response (DoR)
Through study completion, estimated as 57 months
Disease control rate (DCR)
Through study completion, estimated as 57 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1: Monotherapy Dose-escalationEXPERIMENTALOral treatment with IAM1363 capsules, administered in increasing dose levels starting at 120 mg QD in 21-day cycles.
Part 2: Monotherapy Dose OptimizationEXPERIMENTALOral treatment with IAM1363 capsules, administered in 21-day cycles. Participants randomized to receive either 960 mg QD or 1200 mg QD.
Part 3: Monotherapy Dose ExpansionEXPERIMENTALOral treatment with IAM1363 capsules or tablets, administered in up to 5 cohorts at 960 mg QD in 21-day cycles.
Part 4: Combination CohortsEXPERIMENTALOral treatment with IAM1363 capsules or tablets, administered in combination with either capecitabine + trastuzumab (HER2+ metastatic breast cancer), capecitabine + zanidatamab (HER2+ metastatic breast cancer), T-Dxd (HER2+ gastroesophageal adenocarcinoma), and pembrolizumab +/- carboplatin +/- pemetrexed (HER2 amplified or overexpressing non-squamous NSCLC) in 14 or 21-day cycles.

Interventions

NameTypeDescription
IAM1363DRUGIAM1363 monotherapy
Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumabDRUGCohort 4A
Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamabDRUGCohort 4B
Oral treatment with IAM1363 capsules or tablets, administered in combination with T-DxdDRUGCohort 4C
Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexedDRUGCohort 4D
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites53

Key Inclusion Criteria: * Age ≥ 18 years (or adult age per local regulations for the country) * Have relapsed/refractory HER2-altered malignancy; for selected cohorts, prospective confirmation of HER2 alteration by central testing is required * Have progression of disease after the last systemic th...

Countries:United StatesFranceIrelandItalyNetherlandsSouth KoreaSpainUnited Kingdom
Unlock Eligibility Criteria